- Home
- KPTI vs GNTA Comparison
KPTI vs GNTA Comparison
Compare KPTI & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPTI | GNTA |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 33.8M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KPTI | GNTA |
|---|---|---|
| Price | $0.88 | $0.81 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 55.5K |
| Earning Date | 11-02-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.20 | $0.55 |
| 52 Week High | $10.99 | $10.00 |
Technical Indicators
Market Signals| Indicator | KPTI | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 23.57 | 32.19 |
| Support Level | N/A | $0.71 |
| Resistance Level | $2.16 | $0.74 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 0.00 | 26.81 |
Price Performance
Historical ComparisonAbout KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
About GNTA Genenta Science S.p.A.
Genenta Science SPA is an industrial consolidator focused on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its acquisition activities span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity, with a focus on businesses covered by Italy's Golden Power legislation.